LNTH - Lantheus Holdings, Inc. 0 WATCHERS

LNTH Lantheus stock LNTH Lantheus stock, watch for an upside gap breakout [LNTH Lantheus stock chart](https://preview.redd.it/hwrfjjerps4g1.png?width=1627&format=png&auto=webp&s=8c28fab26fc798a3aa23fe5e83c32b5ca747d5d4)

I have and I’ll tell you the position. It was LNTH. I bought in late 2017 and they plunged to $10 a share eventually. Btw, I’m still a shareholder. I haven’t sold a single share of my original position that I started. The reason? Because I know what I own …

Thoughts on my stock picks? Hi all, I’ve been picking stocks for about 5 years now mainly as a hobby since I mostly index invest(even though the below feels like an index lol) so my research isn’t super thorough on each pick. Hoping some of them will be a refreshing …

Monthly Update of my value portfolio I have the below value tickers and they have been greatly underperforming until recently 1. Lly from -35% to 20% 2. Mrk from -33% to -13% 3. PFE sold last month at -20% long term loss 4. Psx -29% to -14% 5. Cop -22% …

WM, LNTH, AWK

LNTH is a undervalued biotech play. Could be a biotech Cash Cow 🐮. In 12 years, they finally update appropriate use criteria (AUC) for Amyloid and Tau PET Imaging. Now Medicare is covering PET scans. FDA has approved updated labeling for Neuraceq, expanding its indication for selecting patients for amyloid-targeting …

The TAM for Neuraceq is much lower than the TAM for Pylarify. LNTH is still undervalued though. On that I agree with you.

LNTH is a undervalued biotech play. Could be a biotech Cash Cow 🐮. In 12 years, they finally update appropriate use criteria (AUC) for Amyloid and Tau PET Imaging. Now Medicare is covering PET scans. FDA has approved updated labeling for Neuraceq, expanding its indication for selecting patients for amyloid-targeting …

Starting in 2026, LNTH, Neuraceq gets a bigger reimbursement. LNTH is a undervalued play LNTH 2025 July Rates Compared to Proposed 2026 Rates. Neuraceq (Florbetaben f18): July 2025 rate, $1,273.76 2026 new rate, $1,577.13 = 23.8% increase in reimbursement. In June FDA has approved updated labeling for Neuraceq, expanding its …

$LNTH Neuraceq gets a bigger reimbursement. $LNTH is a undervalued play $LNTH 2025 July Rates Compared to Proposed 2026 Rates. Neuraceq (Florbetaben f18): July 2025 rate, $1,273.76 2026 new rate, $1,577.13 = 23.8% increase in reimbursement. In June FDA has approved updated labeling for Neuraceq, expanding its indication for selecting …

WM, LNTH

WMT, RSG, and WM are all great, stable businesses. But all 3 of them are horrendously overvalued right now which could seriously limit any potential upside if you're buying at their current share prices. PGR might have some modest undervaluation. I'd say MO is finally trading around fair price, not …